Myeloma Crowd Radio

Upcoming Shows

The Explosion of New Myeloma Therapies – an IMWG Rome Review and ASH Preview with Dr. Ola Landgren, MD, PhD, MSKCC, Friday, Nov 20 @ 1 pm Est


Friday, November 20, 10 am PST, 11 am MST, Noon CST, 1 pm EST

Call In by Phone to Listen Live: (347) 637-2631 or Listen Live Via Computer

New developments for multiple myeloma are happening at an ever increasing pace and one important conference has just concluded while another is happening soon. Dr. Ola Landgren is a thought leader in myeloma and is heavily involved in crafting the direction of myeloma research, both nationally and internationally. In this show he will give a wrap up of the recent Rome International Myeloma Working Group meeting as well as an ASH preview (for the upcoming December conference). He will also share open and upcoming clinical trials at Memorial Sloan Kettering Cancer Center to incorporate these new treatments into clinical practice. Learn what new drugs will be available and how they can be used in the myeloma clinic.

Dr. Landgren is Chief of the Myeloma Service at Memorial Sloan Kettering Cancer Center. Formerly, he was a senior investigator in the Metabolism Branch at the Center for Cancer Research, the National Cancer Institute in Bethesda, Maryland and is also the head of the Multiple Myeloma Section of the Medical Oncology Branch. Dr. Landgren is from Sweden and received his M.D. and Ph.D. degrees in Sweden at the Karolinska Institute and joined the National Cancer Institute in 2004. His major research interests are in the causes of myeloma and how myeloma is diagnosed and treated particularly in the early stages of MGUS and smoldering myeloma. He was a pioneer in defining the standards for minimal residual disease (MRD) testing in myeloma and was a key figure in the IMF Black Swan Research Initiative. In collaboration with colleagues at MSK as well nationally/internationally, he develops new strategies (including cell-based, molecular-based, and imaging-based) to implement advanced MRD testing in clinical trials at MSK and minimal residual disease. His research also includes how the immune system both affects myeloma and how it is affected by myeloma.
Thanks to our episode sponsor, Takeda OncologyTakeda-300x100

Myeloma Crowd Radio Episodes